Compare AGIO & LADR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGIO | LADR |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2013 | 2014 |
| Metric | AGIO | LADR |
|---|---|---|
| Price | $26.97 | $11.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $32.13 | $12.75 |
| AVG Volume (30 Days) | ★ 2.7M | 687.5K |
| Earning Date | 10-30-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 8.09% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.63 |
| Revenue | $44,791,000.00 | ★ $233,492,000.00 |
| Revenue This Year | $28.75 | N/A |
| Revenue Next Year | $139.45 | $6.81 |
| P/E Ratio | ★ N/A | $18.06 |
| Revenue Growth | ★ 36.26 | N/A |
| 52 Week Low | $22.24 | $9.68 |
| 52 Week High | $46.00 | $12.10 |
| Indicator | AGIO | LADR |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 64.57 |
| Support Level | $26.80 | $10.79 |
| Resistance Level | $28.61 | $11.48 |
| Average True Range (ATR) | 1.15 | 0.18 |
| MACD | 0.28 | 0.05 |
| Stochastic Oscillator | 16.59 | 71.74 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments include loans: which derives maximum profit; securities; and real estate.